Table 2.
Sample characteristics of discovery cohorts of European-American and European-Australian (EA) individuals included in meta-analysis (CATS, COGA-cc, COGA-f, OZALC+, SAGE), replication cohort (Yale-Penn) and neuroimaging extension (DNS) samples. Only individuals with a lifetime history of ever using cannabis are included.
| Study | Ncase | Ncontrols | Median age | % Male | % Alcohol dependent | % Nicotine dependent | % Cocaine dependent | % Opioid dependent |
|---|---|---|---|---|---|---|---|---|
| Discovery Samples | ||||||||
| CATS | 799 | 813 | 36 | 57.5 % | 38.8 % | 60.2 % | 24.8 % | 76.1 % |
| COGA-cc | 311 | 593 | 40 | 60.1 % | 79.4 % | 49.0 % | 34.4 % | 13.3 % |
| COGA-f | 368 | 894 | 36 | 50.6 % | 47.0 % | 40.3 % | 13.9 % | 5.7 % |
| OZALC | 357 | 3094 | 43 | 51.7 % | 40.2 % | 50.7 % | 0.4 % | 0.5 % |
| SAGE | 245 | 1041 | 38 | 46.4 % | 55.0 % | 53.4 % | 25.2 % | 9.3 % |
| Replication Samples | ||||||||
| Yale-Penn EA | 781 | 1591 | 38 | 57.7 % | 74.2% | 77.3 % | 78.9 % | 62.0 % |
| Yale-Penn AA | 896 | 1905 | 42 | 54.6 % | 59.9 % | 57.5 % | 75.6 % | 21.2 % |
| Neuroimaging Sample | ||||||||
| DNS | - | - | 19 | 46.7% | 6.3% | 0% | 0% | 0% |
CATS: Comorbidity and Trauma Study; COGA-cc: Case-control component of the Collaborative Study of the Genetics of Alcoholism, COGA-f: family-based component of the Collaborative Study of the Genetics of Alcoholism; OZALC+: Australian alcohol, nicotine and trauma studies; SAGE: Study of Addictions: Genes and Environment; DNS: Duke Neurogenetics Study.